{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir%2C+tenofovir%2Femtricitabine&page=2", "query": { "intervention": "Raltegravir, tenofovir/emtricitabine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 45, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir%2C+tenofovir%2Femtricitabine&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Raltegravir%2C+tenofovir%2Femtricitabine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T21:28:42.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00863668", "title": "Raltegravir Activity In Lymphoid Tissues", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infection", "HIV Infections" ], "interventions": [ { "name": "Efavirenz + Tenofovir DF/Emtricitabine", "type": "DRUG" }, { "name": "Raltegravir + Tenofovir DF/Emtricitabine", "type": "DRUG" }, { "name": "Colonoscopy with biopsies", "type": "PROCEDURE" }, { "name": "Inguinal Lymph Node Excision", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-03", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2015-05-18", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00863668" }, { "nct_id": "NCT00752856", "title": "Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Kaletra + Isentress", "type": "DRUG" }, { "name": "Atripla", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2008-08-26", "completion_date": "2014-02-11", "has_results": true, "last_update_posted_date": "2020-07-22", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 6, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752856" }, { "nct_id": "NCT01332227", "title": "Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV, Combination Therapy" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir (heat-stable)", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2011-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332227" }, { "nct_id": "NCT01025427", "title": "HIV Persistence and Viral Reservoirs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "Raltegravir, tenofovir/emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2020-07-01", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01025427" }, { "nct_id": "NCT00708162", "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Elvitegravir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "EVG placebo", "type": "DRUG" }, { "name": "RAL placebo", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2008-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 94, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708162" }, { "nct_id": "NCT00654147", "title": "Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir & Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Raltegravir and emtricitabine/tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Margaret A. Fischl, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2008-04", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-08-03", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00654147" }, { "nct_id": "NCT00811954", "title": "Comparative Study of Three NNRTI-Sparing HAART Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Emtricitabine/tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Atazanavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1814, "start_date": "2009-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811954" }, { "nct_id": "NCT01456962", "title": "Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Women's Health", "HIV Infection", "Genital Diseases, Female" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 36, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456962" }, { "nct_id": "NCT02605954", "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "Third Antiretroviral Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-11-18", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605954" }, { "nct_id": "NCT00042289", "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "atazanavir/cobicistat", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "elvitegravir/cobicistat", "type": "DRUG" }, { "name": "dolutegravir", "type": "DRUG" }, { "name": "tenofovir alafenamide fumarate (TAF)", "type": "DRUG" }, { "name": "TAF w/cobicistat", "type": "DRUG" }, { "name": "TAF w/cobicistat or ritonavir", "type": "DRUG" }, { "name": "efavirenz", "type": "DRUG" }, { "name": "darunavir/cobicistat", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "atazanavir/ritonavir/tenofovir dosage #1", "type": "DRUG" }, { "name": "rifampicin", "type": "DRUG" }, { "name": "ethambutol", "type": "DRUG" }, { "name": "isoniazid", "type": "DRUG" }, { "name": "pyrazinamide", "type": "DRUG" }, { "name": "kanamycin", "type": "DRUG" }, { "name": "amikacin", "type": "DRUG" }, { "name": "capreomycin", "type": "DRUG" }, { "name": "moxifloxacin", "type": "DRUG" }, { "name": "levoflaxacin", "type": "DRUG" }, { "name": "ofloxacin", "type": "DRUG" }, { "name": "ethionamide/prothionamide", "type": "DRUG" }, { "name": "terizidone/cycloserine", "type": "DRUG" }, { "name": "para-aminosalicylic acid (PAS)", "type": "DRUG" }, { "name": "high dose INH", "type": "DRUG" }, { "name": "bedaquiline", "type": "DRUG" }, { "name": "clofazamine", "type": "DRUG" }, { "name": "delamanid", "type": "DRUG" }, { "name": "linezolid", "type": "DRUG" }, { "name": "pretomanid", "type": "DRUG" }, { "name": "ethinyl estradiol", "type": "DRUG" }, { "name": "etonogestrel implant", "type": "DRUG" }, { "name": "nevirapine", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "abacavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "fosamprenavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #3", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #1", "type": "DRUG" }, { "name": "didanosine delayed release (Videx® EC)", "type": "DRUG" }, { "name": "emtricitabine", "type": "DRUG" }, { "name": "tenofovir", "type": "DRUG" }, { "name": "nelfinavir dosage #1", "type": "DRUG" }, { "name": "tipranavir/ritonavir", "type": "DRUG" }, { "name": "lopinavir/ritonavir dosage #4", "type": "DRUG" }, { "name": "raltegravir", "type": "DRUG" }, { "name": "etravirine", "type": "DRUG" }, { "name": "maraviroc", "type": "DRUG" }, { "name": "atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "tenofovir/atazanavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "nelfinavir dosage #2", "type": "DRUG" }, { "name": "indinavir/ritonavir dosage #2", "type": "DRUG" }, { "name": "rilpivirine", "type": "DRUG" }, { "name": "darunavir/ritonavir dosage #4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1578, "start_date": "2003-06-09", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-10T21:28:42.334Z", "location_count": 39, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00042289" } ] }